Abstract: Disclosed herein, in part, are methods of subcutaneously administering liquid pharmaceutical formulations containing furosemide to a patient using a shortened infusion profile. Methods of treating condition such as congestion due to fluid overload, oedema, or hypertension in a patient in need thereof are also provided.

Abstract: In some embodiments, a noise reduction circuit comprises an insulated wire comprising a conductor and insulation. A shielding material is oriented around the insulated wire. The shielding material comprises metallized fibers.

Abstract: Systems and methods may be provided to receive, at a server, a utility bill and interval data for a user of an energy utility, and store the received utility bill and interval data in a database system communicatively coupled to the server. The received utility bill may include a date range for the bill and a tariff. The received interval data may include data used by the energy utility for determining costs. A calculation engine of the server may determine a model bill based on the received utility bill and the interval data. The server may determine an accuracy of a utility bill issued by the energy utility to by determining whether the model bill matches the utility bill. The server may determine that the utility bill, the interval data, and the tariff are accurate when the model bill matches the utility bill based on the accuracy determination.

Abstract: Systems and methods may be provided to receive, at a server, a utility bill and interval data for a user of an energy utility, and store the received utility bill and interval data in a database system communicatively coupled to the server. The received utility bill may include a date range for the bill and a tariff. The received interval data may include data used by the energy utility for determining costs. A calculation engine of the server may determine a model bill based on the received utility bill and the interval data. The server may determine an accuracy of a utility bill issued by the energy utility to by determining whether the model bill matches the utility bill. The server may verify the utility bill, the interval data, and the tariff as accurate when the model bill matches the utility bill based on the accuracy determination.

Abstract: Disclosed herein, in part, are methods of subcutaneously administering liquid pharmaceutical formulations of furosemide to an adult patient from a prefilled cartridge using a five-hour bi-phasic delivery profile. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.

Abstract: The present application relates to processes for making (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b -hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl (S)-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), which is an inhibitor of vesicular monoamine transporter 2 (VMAT2) useful in the treatment of hyperkinetic movement disorders such as tardive dyskinesia (TD).

Abstract: In some embodiments, a noise reduction circuit comprises an insulated wire comprising a conductor and insulation. A shielding material is oriented around the insulated wire. The shielding material comprises metallized fibers.

Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).

Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).

Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).

Abstract: This pistol dry fire device enables multiple dry fire trigger pulls with just one racking of the slide or cocking of the semi-automatic double action only pistol without any modifications to the pistol or the standard magazine. Since the device is constructed from an impact resistant material that is inserted behind the slide and in front of the flush mounted hammer, the hammer does not contact the firing in when the device is properly positioned, rotated 90 degrees and locked in place, preventing damage to the pin, but does allow the hammer to fall and the trigger to reset as when live fire is conducted. This reset then allows for another trigger pull without racking the slide. The device also creates a visual failsafe condition without interfering with the pistol's normal functions or sights.

Abstract: Telecommunications equipment may require network connectivity. On newer systems, an additional local management interface is provided for proprietary maintenance functions, typically via a shell-based Command Line Interface. This is not available on remote sites with only TDM connections. The invention provides a method of communicating between a management console and remote access equipment via a class 4 telecommunications switch, which comprises establishing an IP connection, establishing a synchronous telecommunications transport connection between the class 5 switch and the remote access equipment, setting up a voice call between the management console and the remote access equipment, passing the voice call over the IP connection as a VOIP call, passing the voice call over the synchronous telecommunications transport connection as a PCM encoded call, and encapsulating an IP data stream in the VOIP and PCM encoded call to establish an end-to-end IP.

Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).

Abstract: Audio amplification may be improved by controlling an audio amplifier based on the audio signal being amplified. For example, when the audio signal level increases or decreases, a boost voltage provided to an audio amplifier by a boost converter may also be increased or decreased. In another example, when the audio signal level decrease below a certain level, the audio amplifier may be switched from amplifying the audio signal with a boost converter input to amplifying the audio signal with a low voltage input. Control of the audio amplifier may be implemented in a digital boost converter controller coupled to the boost converter and/or the audio amplifier.

Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).

Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).

Abstract: Audio amplification may be improved by controlling an audio amplifier based on the audio signal being amplified. For example, when the audio signal level increases or decreases, a boost voltage provided to an audio amplifier by a boost converter may also be increased or decreased. In another example, when the audio signal level decrease below a certain level, the audio amplifier may be switched from amplifying the audio signal with a boost converter input to amplifying the audio signal with a low voltage input. Control of the audio amplifier may be implemented in a digital boost converter controller coupled to the boost converter and/or the audio amplifier.

Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).

Abstract: Existing telecommunications equipment may require network connectivity for data transfer but may have no external interfaces except for the TDM voice circuits to which they are connected. Thus on most newer systems, an additional local management interface is provided for proprietary maintenance functions. This is typically accessed via a shell-based Command Line Interface. This cannot be used on a remote site with only TDM connections.